Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Spinal stimulation implant offers new hope for Parkinson’s disease treatment

The implant was tested to correct gait disorders associated with advanced cases of the disease

Isolation-in-the-internet-age

Isolation in the internet age

Productivity is what ours and most other industries need to optimise in order to thrive. And we all want to do a good job for ourselves and our clients. However,...

Mednet

- PMLiVE

Honoring Educational Partners at ACG

The recent ACG conference was an opportunity for members of the Medscape team to shine a light on their educational partners and honor them for their exceptional work.On October 21,...

Medscape Education

- PMLiVE

MHRA authorises anastrozole to prevent breast cancer in post-menopausal women

The treatment could help prevent around 2,000 breast cancer cases in England

- PMLiVE

US FTC challenges more than 100 patents as ‘improperly listed’ with FDA

The agency has sent letters to ten companies including AbbVie, AstraZeneca and GSK

- PMLiVE

Janssen reveals positive results for nipocalimab in rheumatoid arthritis

About 13 million people worldwide are affected by the chronic inflammatory disease

- PMLiVE

NICE announces launch of refreshed support service for life sciences industry

NICE Advice will support pharmaceutical and healthtech companies and provide patients with access to quality treatments and care

- PMLiVE

Cancer Research UK and KWF Dutch Cancer Society partner for drug development

More than 390,000 people are diagnosed with cancer every year in the UK

Clinical trials explained: Why colour matters…

Colour can be used to emphasise mood, evoke emotions, and determine first impressions of a brand. Find how to use colour effectively in your next clinical trial campaign.

Cuttsy + Cuttsy

- PMLiVE

BioNTech acquires right to Biotheus’ bispecific antibody candidate in deal worth over $1bn

PM8002 is currently being evaluated in phase 2 studies in patients with advanced solid tumours

- PMLiVE

Bristol Myers Squibb to acquire Orum’s experimental blood cancer therapy for up to $180m

ORM-6151 has been cleared for early-stage testing in AML or myelodysplastic syndromes

EU flag

EFPIA research suggests EU proposal could further pharma innovation decline

EU incentives to invest in medicines will reduce by 55% over the next 15 years

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links